Immunocore Holdings (IMCR) Interest Expenses (2021 - 2026)

Immunocore Holdings (IMCR) has reported Interest Expenses for 6 consecutive years, with $69.3 million the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses rose 1276.86% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (up 235.68% YoY) and the FY2025 annual result came in at $200.1 million, up 117.07% from the prior year.
• Interest Expenses climbed to $69.3 million in Q1 2026 per IMCR's latest filing, from $3.1 million in the prior quarter.
• Over the last five years, Interest Expenses for IMCR reached as high as $326.1 million in Q1 2024 and fell as low as $788000.0 in Q4 2023.
• A 5-year average of $31.8 million and a median of $3.4 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses soared 25990.48% — and 2025, when it slumped 98.46%.
• Year by year, Interest Expenses stood at $3.7 million in 2022, then plunged by 78.85% to $788000.0 in 2023, then jumped by 793.15% to $7.0 million in 2024, then slumped by 56.62% to $3.1 million in 2025, then soared by 2168.92% to $69.3 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $69.3 million, $3.1 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.